drugset / Trial / NCT00005875

Nitrocamptothecin in Treating Patients With Metastatic Melanoma

NCT00005875

Phase 2 Completed Astex Pharmaceuticals, Inc.
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have metastatic melanoma.

Timeline

Start
1999-01
Primary completion
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject rubitecan Unknown Oral

Indications